These highlights do not include all the information needed to use YUSIMRY safely and effectively. See full prescribing information for YUSIMRY.YUSIMRY (adalimumab-aqvh) injection, for subcutaneous useInitial U.S. Approval: 2021 YUSIMRY (adalimumab-aqvh) is biosimilarBiosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product. Biosimilarity of YUSIMRY has been demonstrated for the condition(s) of use (e.g., indication(s), dosing regimen(s), strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information. to HUMIRA (adalimumab)

Patient Home

Welcome to Health Vidya. Discover trusted care and your own health — all in one place.

These highlights do not include all the information needed to use YUSIMRY safely and effectively. See full prescribing information for YUSIMRY.YUSIMRY (adalimumab-aqvh) injection, for subcutaneous useInitial U.S. Approval: 2021 YUSIMRY (adalimumab-aqvh) is biosimilarBiosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product. Biosimilarity of YUSIMRY has been demonstrated for the condition(s) of use (e.g., indication(s), dosing regimen(s), strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information. to HUMIRA (adalimumab)

Medication label

Why this: Advisory · dailymed-prescription

YUSIMRY is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. YUSIMRY can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs). YUSIMRY is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. YUSIMRY can be used alone or in combination with methotrexate. YUSIMRY is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. YUSIMRY can be used alone or in combination with non-biologic DMARDs. YUSIMRY is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis. YUSIMRY is indicated for the treatment of moderately to severely active Crohn's disease in adults and pediatric patients 6 years of age and older. YUSIMRY is indicated for the treatment of moderately to severely active ulcerative colitis in adult patients. Limitations of Use The effectiveness of adalimumab products has not been established in patients who have lost response to or were intolerant to TNF blockers [see Clinical Studies (14.7)]. YUSIMRY is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. YUSIMRY should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician [see Warnings and Precautions (5)]. YUSIMRY is indicated for the treatment of moderate to severe hidradenitis suppurativa in adult patients. YUSIMRY is indicated for the treatment of non-infectious intermediate, posterior, and panuveitis in adult patients.

generic_name: adalimumab-aqvh
product_names: adalimumab-aqvh
ndc: 70114-210, 70114-210-02, 70114-220, 70114-220-02
group: drugs
license: us-gov-pd
attribution: Courtesy of the National Library of Medicine
reviewed: 2026-09-18
language: en